Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva    VLA   FR0004056851

VALNEVA (VLA)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CEST

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA
05/17VALNEVA : Researchers Submit Patent Application, "Aseptic Purification Process f..
AQ
05/17VALNEVA : Reports Strong Q1 Results and Continues to Advance Key R&D Programs
GL
05/17VALNEVA : Reports Strong Q1 Results and Continues to Advance Key R&D Programs
AQ
05/17VALNEVA : 1st quarter earnings
CO
05/14VALNEVA SE : quaterly earnings release
03/29VALNEVA : to Present on Lyme and Zika at the 18th World Vaccine Congress in Wash..
GL
03/22VALNEVA : Delivers Strong 2017 Financial Results and Advances Key R&D Programs
GL
03/19VALNEVA : Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidat..
GL
03/19VALNEVA : Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidat..
AQ
03/14VALNEVA : Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine C..
AQ
More news
News from SeekingAlpha
05/17Valneva SE reports Q1 results 
04/05Valneva (INRLF) Presents At World Vaccine Congress Washington 2018 - Slidesho.. 
03/26Valneva SE 2017 Q4 - Results - Earnings Call Slides 
03/23Valneva's (INRLF) CEO Thomas Lingelbach on Q4 2017 Results - Earnings Call Tr.. 
03/22Valneva SE reports FY results 
Financials (€)
Sales 2018 118 M
EBIT 2018 -0,45 M
Net income 2018 -8,75 M
Debt 2018 39,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 1 216,67
EV / Sales 2018 2,96x
EV / Sales 2019 2,63x
Capitalization 311 M
Chart VALNEVA
Duration : Period :
Valneva Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Technical analysis trends VALNEVA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 4,85 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Grimaud Co-President & Chief Business Officer
Frédéric Grimaud Chairman-Supervisory Board
David Lawrence Chief Financial Officer
Wolfgang Bender Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA46.75%364
CELLTRION, INC.--.--%29 932
IQVIA HOLDINGS INC4.64%21 220
LONZA GROUP1.41%20 059
NEKTAR THERAPEUTICS42.83%14 179
INCYTE CORPORATION-29.71%14 111